OBJECTIVE: It has been reported that an increased availability of free fatty acids (NEFA) not only interferes with glucose utilization in insulin-dependent tissues, but may also result in an uncoupling effect of heart metabolism. We aimed therefore to investigate the effect of an increased availability of NEFA on gene expression of proteins involved in transmembrane fatty acid (FAT=CD36) and glucose (GLUT4) transport and of the uncoupling proteins UCP2 and 3 at the heart and skeletal muscle level. STUDY DESIGN: Euglycemic hyperinsulinemic clamp was performed after 24 h Intralipid 1 plus heparin or saline infusion in lean Zucker rats. Skeletal and heart muscle glucose utilization was calculated by 2-deoxy-[1- 
Introduction
Plasma free fatty acids (NEFA) are thought to mediate the insulin resistance associated with obesity. Muscle insulin resistance might result from the 'Randle' mechanism, 1 from the downregulation of the insulin signaling pathway, and=or reduced access of insulin to skeletal muscle owing to changes in blood flow or insulin transport across capillary endothelium. 2, 3 At the heart level, where insulin stimulates glucose oxidation, lipid infusion decreases insulin-mediated glucose utilization as measured by the euglycemic hyperinsulinemic clamp technique 4 and positron emission tomography scanning, 5 leaving open the question of whether lipotoxicity may affect not only skeletal muscle, but also heart metabolism in obesity and diabetes. It is well recognized from in vivo studies that, in steady-state conditions, the heart can derive energy for adenosine triphosphate (ATP) production from the preferential oxidation of fatty acids and, to a lesser extent, from glucose oxidation. As a general rule, the actual workload, the need for energy supply, the relative substrate availability and the hormonal milieu are the factors that determine the pattern of substrate utilization by heart muscle. Physiological hyperinsulinemia, as can be observed after a normal meal, has been reported to provoke a shift from fat to carbohydrate fuel utilization. 6 On the other hand, in the diabetic rat heart, NEFA represent the major source of myocardial oxidative metabolism, because of the sharp reduction of glucose utilization due to the lack of insulin 7 and possibly to the large decrease in GLUT4 mRNA. 8 However the latter issue is still controversial and at present no conclusive data are available to support the hypothesis that changes in lipid substrate supply may affect cardiac GLUT4. 9 Because of the hydrophobic nature of NEFA, it has generally been assumed that they can rapidly traverse the lipid bilayer of the cell membrane by their mass action. However NEFA may also enter the cell via a carrier-mediated process in many cells, including cardiac myocytes 10 and adipocytes.
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FAT=CD36 is a transmembrane transporter of long-chain fatty acids, 12 which in turn have been shown to upregulate the fatty acid translocase itself. 13 -16 Oxidative muscles exhibit much greater NEFA transport rates than white glycolytic muscles probably because of the greater FAT=CD36 mRNA and protein content in the former than in the latter. Because red muscles and heart both exhibit a high capacity for NEFA metabolism, it is also possible that the NEFA transporter FAT=CD36 may be equally stimulated in conditions of increased NEFA availability.
It has been reported that very high NEFA concentrations induce uncoupling of heart muscle mitochondria, thus decreasing the respiration-generated membrane potential, through mechanisms that are still not fully clarified, and an involvement of the ATP=ADP antiporter and=or uncoupling proteins (UCPs) has been hypothesized. 17, 18 The newly discovered UCP2 is widely expressed in several tissues, and particularly in the normal rat heart muscle under basal conditions. 19 UCP3 is predominantly expressed in skeletal muscles and only slightly detectable in rat heart muscle. 20 -22 In the diabetic rat heart, in spite of a reported increased NEFA oxidation, the intracellular concentration of ATP was reported to be low, 23 resulting from an uncoupling of oxidative phosphorylation that has been hypothesized to be linked to an increased gene expression of UCP3. 24 The aim of the present study was therefore to investigate the effects of an increased availability of NEFA on heart insulin-dependent glucose metabolism and on GLUT4 mRNA. Moreover, the expression of genes encoding specific fatty acid-binding protein (FAT=CD36) and UCP2 and 3, potentially involved in the control of heart muscle bioenergetics, was also investigated and compared with the changes occurring at the skeletal muscle level.
Materials and methods

Animals
Male lean Zucker rats, initially weighing 180 -190 g, were purchased from Charles River (Lecco, Italy). They were housed in a room with regulated temperature (22 AE 2 C) and light-dark cycle (12:12) . All animals were maintained on a standard diet with water ad libitum. After a 3 day acclimatization period, rats were randomly assigned to one of two groups designated as Intralipid 1 infusion (n ¼ 12) or control saline infused (n ¼ 12). All animals were studied after an overnight fast. All experiments were approved by the animal ethics committee of our institution, and were performed in accordance with the Helsinki accords for humane treatment of laboratory animals.
Surgical procedure
All rats were anesthetized with an intra-peritoneal injection of 50 mg=kg of chloral hydrate (Merck, Damstadt, Germany). When surgical anesthesia was confirmed by the absence of corneal and toe-pinch reflexes, a Tygon catheter (Masterflex Cole-Parmer Instrument Company, Niles, IL, USA) filled with a saline solution was inserted into the right femoral vein and artery, respectively for venous infusion and blood sampling. At the end of anesthesia the animals were placed in individual cages with a single exit slot for the catheters, which were maintained in continuous tension. A slow infusion of saline solution was used to prevent any blockage in the arterial catheter. The animals were freely moving.
Glucose clamp during Intralipid
1 plus heparin or saline plus heparin infusion In a first group of six rats, after 24 h recovery from surgery, an infusion of Intralipid 1 20% (a commercial emulsion of soybean oil, Pharmacia AB-Sweden) was i.v. infused at 0.7 ml=h (0.0023 g=min) with heparin sodium (0.4 U=min=kg) for 24 h, whilst a second group of six animals was infused with saline plus heparin sodium at the same flow rate. Blood samples were collected before the beginning of the infusion for the determination of basal blood glucose, plasma insulin, NEFA. After the 24 h Intralipid 1 plus heparin or saline plus heparin infusion a primed-continuous infusion of human insulin (Actrapid HM, Novo, Copenhagen, Denmark; dissolved in 0.9% saline solution) at a rate of 3 mU=min was performed. Blood samples for plasma glucose, NEFA and insulin were collected before the beginning and at the end of clamp. Arterial blood was sampled at 5 min intervals throughout the clamp for determination of plasma glucose concentration. Glucose infusion (20% w=v solution) was commenced 1 min after the beginning of insulin infusion. The glucose infusion rate was adjusted to maintain plasma glucose at the preinfusion levels as previously described. 25 Tissue glucose utilization index Glucose utilization in vivo within heart and skeletal muscle was studied in a first group of six rats in basal conditions, after a 24 h Intralipid 1 plus heparin or saline plus heparin infusion. In a second group of six animals, treated with either Intralipid 1 plus heparin or saline infusion, heart NEFA and gene expression in rat heart R Vettor et al glucose utilization index was assessed during the euglycemic hyperinsulinemic clamp.
, the non metabolizable glucose analog, was injected as a bolus (30 mCi in 30 ml of 0.9% NaCl solution) through the femoral vein according to a previously described method. 26, 27 Blood samples for determination of plasma glucose and tracer concentrations were obtained from the arterial catheter 1, 3, 5, 10, 15, 20, 30, 40 and 60 min after bolus administration.
At the completion of blood sampling, the rats were killed and the ventricular portion of the heart and the soleus muscle were quickly removed and cleaned of adipose tissue, gently washed in cold saline solution, immediately frozen in liquid nitrogen and kept at 7 80 C for the subsequent analysis.
The glucose utilization index was derived from the amount of 2-deoxy-1-
) measured in various tissues that we considered to be an index of the tissue glucose metabolic rate as previously described. 26 Quantification of GLUT4, UCP2 and UCP3 mRNAs In a separate series of experiments two group of six rats, infused with either Intralipid 1 plus heparin or saline plus heparin as described above, were killed and the tissues were immediately removed, rinsed in NaCl solution and frozen in liquid nitrogen. Total mRNA was isolated using the TRIAzol method (Gibco BRL Grand Island, NY, USA). 28 The concentration of RNA was determined by absorbance at 260 nm, and the RNA was stored at 7 80 C. All the samples had a 260 -280 absorbance ratio about 2.0. The RNA (20 mg) was denatured and size fractionated on a 1% agarose, 2 M formaldehyde gel. After staining (0.5 mg=ml ethidium bromide), the 28 S and 18 S ribosomal bands were visualized and photographed by ultraviolet transillumination to ensure that the RNA was intact and evenly loaded. The RNA was then transferred to Hybond-N, UV cross-linked. The cDNA probe of the rat GLUT4 (1.5 Kb insert) was used. Blots were also probed with a 32 P-labeled mouse UCP2 cDNA cloned from a skeletal muscle cDNA library (GenBank accession number for mouse UCP2 probe is AF096288) and a 32 Plabeled mouse UCP3 cDNA cloned from a skeletal muscle cDNA library (GenBank accession number AF032902) and then with an actin cDNA. Northern blots and hybridation were performed as previously described. 29 After autoradiography, the hybridization signals were quantified by densitometry. Since UCP3 was only slightly detectable in rat heart we measured UCP3 by RT-PCR.
RT-PCR assay of UCP3 and FAT=CD36
Total RNA was isolated from heart and skeletal muscle using the RNAzol method (TM Cinna Scientific, Friendswood, TX, USA). The RNAs were treated for 1 h at 37 C with six units of RNAse-free DNAse I=mg RNA in 100 mM Tris-HCl, pH 7.5, and 50 mM MgCl 2 in the presence of 2 units=ml of placenta RNAse inhibitor. All of RNAs were reverse-transcribed with 200 units of Moloney murine leukemia virus reverse transcriptase (Promega) in 20 ml of buffer containing 0.4 mM dNTPs, 2 units=ml RNAse inhibitor, 0.8 mg oligo(dT) 15 primer (Promega). PCR was performed using Taq DNA polymerase (Promega) in 25 ml of standard buffer (10 mM Tris-HCl, pH 9, 50 mM KCl, 0.1% Triton X-100, 2.5 mM MgCl 2 and 200 mM dNTPs) and 40 pmol of each sense-and antisensespecific oligonucleotide primer. The primer sequences were chosen using GeneWorks program (IntelliGenetics Inc., USA) and were: 5 0 -ACG GAT GTG GTG AAG GTC CG-3 0 and 5 0 -TAC AAA CAT CAT CAC GTT CC-3 0 for UCP3 (long), 5 0 -GTT GGC AAG AAG CAA GTG C-3 0 and 5 0 -CAA TGA GTA GGT CTC CAA CCG-3 0 for FAT=CD36. Amplified bands were 473 and 360 bp respectively. The primers for b-actin were as described by Gaudette and Crain 30 and were added at the 10 C cycle of each PCR amplification to avoid a plateau situation. All the genes were amplified using 30 cycles at 94 C for 30 s, 60 C for 30 s and 72 C for 30 s, followed by 5 min final extension at 72 C. After amplification, 10 ml of the reaction mixture were separated by electrophoresis (1.2% agarose gel in Tris -acetate -EDTA buffer), visualized using ethidium bromide staining, revealed with a QuickImage-D (Canberra Packard, Milan, Italy) and densitometrically analyzed with Phoretix 1D version 3.0. The number of cycles for the semiquantitative RT-PCR analysis and the conditions of the reaction temperature were estimated to be optimal for a linear relationship between the amount of input template and the amounts of PCR product generated over a significant concentration range: 20 -100 ng from total RNA. In particular the linearity of the RT-PCR amplifications for all the tested genes were measured at 15, 30 and 40 cycles (data not shown). The RT-PCR analyses were performed three times on the same sample for each animal. The intra-assay coefficient of variation was < 5%.
Analytical procedures and calculations
Plasma glucose was measured by the glucose oxydase method (Glucose Analyzer; Beckman Instruments, Inc). Plasma NEFA was determined using a commercial kit (Boehringer Mannheim GmbH, Mannheim, Germany; Boehringer Mannheim KK, Tokyo, Japan).
Basal insulin was determined by a radioimmunoassay using an antibody raised against rat insulin and serial dilution of rat insulin as standard (Linco Research, St Charles, MO, USA). The end of clamp plasma insulin was measured using an immunoradiometric assay with two monoclonal antibodies against human insulin and dilution of human insulin as standards.
Blood samples (50 ml) for determination of [ 3 H]2DG specific activity were deproteinized with 250 ml ZnSO 4 and 250 ml Ba(OH) 2 and immediately centrifuged. After measurement of glucose concentration with a glucose oxidase kit (Boehringer, Mannheim, Germany), an aliquot of the NEFA and gene expression in rat heart R Vettor et al supernatant was evaporated to dryness at 70 C, resuspended in water and counted in scintillation fluid (Instagel, Packard, USA) in order to determine [ 3 H]2DG plasma radioactivity. Determination of [
3 H]2D-glucose-6-phosphate was performed taking into account its non-solubility in the Somogy reagent system. Briefly, tissue solubilization was obtained adding in each tube 0.5 ml of NaOH (1 N). After incubation at 80 C until complete digestion the samples were neutralized with 0.5 ml of HCl (1 N). Two aliquots of the neutralized solution were added to 1 ml of HClO 4 (1 N) and to 1 ml of ZnSO 4 =BaOH 2 respectively. 26 Radioactivity was then calculated in the supernatant after centrifugation. 26, 27 and expressed as ng=mg=min.
Statistical analysis
All values are presented as the means AE standard error. Statistical analysis was performed by ANOVA.
Results
Metabolic parameters
The Intralipid 1 infusion significantly raised plasma free fatty acids (from 811.2 AE 56.9 to 1861.7 AE 183.1 mmol=l, P < 0.001) in comparison to saline-treated rats (from 833.9 AE 69.5 to 852.0 AE 54.0 mmol; Figure 1A) . A significant increase in plasma insulin levels was observed at the end of 24h Intralipid 1 infusion (from 35.2 AE 4.8 to 42.2 AE 6.6 mU=l; P < 0.01) compared to salineinfused animals (from 30.1 AE 3.2 to 23.3 AE 3.9 mU=l). In the same experimental conditions we did not observe any significant variation in basal blood glucose either after the fat emulsion administration (from 5.3 AE 0.2 to 5.7 AE 0.2 mmol=l) or in control saline infused rats (from 5.7 AE 0.7 to 5.7 AE 0.3 mmol=l).
Euglycemic hyperinsulinemic clamp
The glucose infusion rate measured in steady-state conditions at the end of clamp was significantly reduced in the Intralipid 1 infused animals in comparison to saline-treated rats (17.89 AE 1.44 vs 38.14 AE 1.74 mg=kg=min; P < 0.001).
The index of glucose utilization in the heart muscle as assessed in basal condition showed no differences between the two groups of animals (14.60 AE 5.39 vs 12.73 AE 2.62 ng=mg=min). On the contrary, the basal glucose utilization index in the soleus muscle was significantly reduced after Intralipid 1 infusion (10.90 AE 1.80 vs 6.07 AE 1.58 ng= mg=min; P < 0.05). In heart tissue the same parameter was significantly reduced in Intralipid 1 infused animals at the end of euglycemic hyperinsulinemic clamp (22.62 AE 2.04 vs 10.37 AE 2.33 ng=mg=min; P < 0.01; Figure 2A ). Tissue glucose utilization index was significantly reduced in the same animals at the soleus muscle level (13.46 AE 1.53 vs 6.84 AE 2.58 ng=mg=min; P < 0.05; Figure 2A ).
Effects on gene expression of FAT=CD36, GLUT 4 and UCP2 and UCP3
In these studies, we chose to define the transcriptional events that induce expression of genes tightly linked with the initial stages of both free fatty acids and glucose uptake, with an emphasis on the FAT=CD36 and on the insulinresponsive glucose transporter GLUT4. The gene expression of FAT=CD36 was significantly increased in Intralipid 1 -infused rats compared to saline-treated animals in skeletal muscle tissue (117.9 AE 16.4%; P < 0.05), but not in heart muscle ( Figure 1B) . The relative abundance of GLUT4 mRNA, as measured by Northern blot analysis, was clearly reduced after 24 h Intralipid 1 infusion in both skeletal (109.0 AE 3.9 vs 156.0 AE 12.0; P < 0.01) and heart muscle (39.6 AE 8.5 vs 140.9 AE 19.6; P < 0.01; Figure (2B) .
To determine whether the UCP homologs were differentially expressed during an increased free fatty acid availability, we compared the relative mRNA levels of UCP2 and 3 in heart and skeletal muscle of normal rats infused with either saline or Intralipid 1 . UCP2 mRNA levels in heart and skeletal muscle increased by 110 AE 8% and 80 AE 4% over the basal value respectively in rats infused with the fat emulsion compared with controls ( Figure 3A) .
RT-PCR was used to measure UCP3 mRNA levels in skeletal muscle and in heart tissue ( Figure 3B ). In the Northern blot analysis, UCP3, unlike the ubiquitously expressed UCP2, has been only slightly detected in heart muscle tissue, the main site of expression being the skeletal muscle. After the administration of the fat emulsion the UCP3 mRNA as assessed by RT-PCR in heart muscle tissue was found to be significantly higher (80 AE 4% over the basal value) than in saline treated animals. In skeletal muscle the mRNA levels of UCP-3, measured with RT-PCR, were found to be significantly higher after Intralipid 1 when compared with the control group ( Figure 3B ).
Discussion
The high NEFA plasma levels reached in our studies lead to an increased availability of lipid fuels that may enter the cells mostly through their mass action or via a specific transporter system. Moreover the early steps of NEFA uptake can also be rapidly modulated by local processes such as the NEFA oxidative capacity of tissues, absolute rates of uptake being greater in continuously working muscles like heart and diaphragm than in red skeletal muscles. 31 In our experimental conditions we observed that NEFA were able to increase skeletal, but not heart muscle fatty acid translocase FAT=CD36 mRNA levels after a 24 h Intralipid 1 infusion. This lack of increase appears to be in contrast with the observation that in FAT=CD36 null mice a considerably reduced heart and skeletal muscle uptake of two iodinated fatty acid analogs has been reported. 32 Moreover both in in vitro 15, 33 and in vivo 34 studies, long-chain fatty acid uptake correlated positively with the expression of FAT=CD36 in NEFA and gene expression in rat heart R Vettor et al both skeletal and heart muscle. However, an increased fatty acid transport at the heart level could be the result of an increased abundance of the transporter on the plasma membrane due to a possible translocation from an intracellular pool, without any changes in fatty acid transporter mRNA levels. 35 Our data also indicate that, in the presence of an excessive NEFA availability, a decreased insulin sensitivity and a Figure 2 (A) Glucose utilization index as assessed during euglycemic hyperinsulinemic clamp in the heart and soleus muscle after Intralipid 1 plus heparin (n ¼ 6) or saline (n ¼ 6) infused animals. (B) Northern blot analysis and quantification of the relative levels of GLUT4 mRNA in heart and in soleus muscle after Intralipid 1 plus heparin (n ¼ 6) or saline (n ¼ 6) infusion. At the top, a representative autoradiograph of Northern blot analysis for GLUT4 and b-actin content in heart and muscle is depicted. The analysis was performed twice on the same sample from each of the 12 rats. Bars represent the mean AE s.e.m. values.
NEFA and gene expression in rat heart R Vettor et al depression of skeletal and heart muscle insulin-mediated glucose uptake occur. In this study we observed a decrease in both soleus and heart muscle GLUT4 gene expression, suggesting that the relative increase in lipid availability may modulate not only skeletal, but also cardiac insulin action through the downregulation of insulin-responsive glucose transporter. It is noteworthy that in hypoinsulinemic conditions, in which an increased mobilization and utilization of NEFA is present, the reduction of myocardial glucose uptake may result from the cellular depletion of GLUT4. 36 These data resemble what occurs in experimental obesity due to high fat, but not high-energy=carbohydrate feeding, in which the degree of insulin-responsive glucose transport in vivo is associated with pretranslational suppression of GLUT4 expression and GLUT4 protein translocation to the plasma membrane in skeletal muscle. 37 -40 The decreased glucose utilization in the presence of high levels of circulating NEFA 1 may lead to a decreased ATP Figure 3 (A) Northern blot analysis and quantification of the relative amounts of UCP2 mRNA in heart and in soleus muscle after Intralipid 1 plus heparin (n ¼ 6) or saline (n ¼ 6) infusion. At the top, a representative autoradiograph of Northern blot analysis for UCP2 and b-actin content in heart and muscle is shown. The analysis was performed two times on the same sample from each of the 12 rats. Bars represent the mean AE s.e.m. values. B: Effect of Intralipid 1 plus heparin or saline infusion on UCP3 mRNA level in soleus and heart muscle after Intralipid 1 plus heparin (n ¼ 6) or saline (n ¼ 6) infusion. At the top, a representative agarose gel showing PCR analysis for UCP3 and b-actin content in heart and muscle is shown. The PCR analysis was performed three times on the same sample from each of the 12 rats. Bars represent the mean AE s.e.m. values.
NEFA and gene expression in rat heart
R Vettor et al formation via glycolysis that, despite being unable to support contraction, is used preferentially to maintain sarcolemmal structural and functional integrity such as several membrane-linked enzymes and ion pumps. 41 Besides inhibition of glucose utilization, very high levels of NEFA may alter membrane fluidity because of the accumulation of toxic products in the sarcolemma, sarcoplasmatic reticulum and mitochondrial membranes. 42 The metabolic and molecular alterations induced by Intralipid 1 infusion at the heart level mimic what observed in db=db mice, in which a correlation between several contractility parameters have been studied. Belke et al 43 observed the presence of contractility dysfunction in db=db mouse hearts tightly linked to a depression of the rate of glycolysis and glucose oxidation, and in contrast to an increase in palmitate oxidation. Both glucose and palmitate metabolism, along with contractility, were normalized in hearts from transgenic db=db mice overexpressing the GLUT4 glucose transporter, suggesting a co-causative role of the impaired glucose metabolism in the cardiomyopathy observed in diabetic mice. Moreover high levels of NEFA may increase myocardial oxygen consumption via fruitless cycling of energy wasting reactions, such as repeated cycles of trygliceride synthesis and lipolysis. Furthermore, a protonophoric action of fatty acids has been also shown in vitro 44 , but not in vivo. 45 This effect has been hypothesized to be related to the chain length and degree of saturation of the NEFA 46 , but so far no clear explanation for these putative uncoupling effects of long-chain NEFA has been proposed.
In this respect the observation of a clear enhancement of both UCP2 and 3 gene expression either in the heart and in skeletal muscle, following the 24 h infusion of fat emulsion, is noteworthy, but at present we do not possess a definitive explanation of the phenomenon. Whether carbohydrate and lipid oxidation affects the control of UCP3 expression has been recently examined 47, 48 and it has been suggested that NEFA oxidation might be a modulator of gene transcription of UCP3. 47 This concept has been further enforced by the observation that cardiac UCP3 mRNA levels markedly increase during fasting, an induction that is completely reversed by nicotinic acid treatment. 49 However a direct stimulatory effect of NEFA on heart UCP2 gene expression is questioned. Data obtained by Van Der Lee et al in adult rat heart failed to demonstrate an increase of UCP2 gene expression in conditions of high NEFA plasma levels due to fasting and streptozotocin-induced diabetes. 50 On the other hand, these experimental conditions appear to be quite different from our model, mainly because of the different levels of insulin. Moreover the fact that in isolated neonatal cardiomyocytes fatty acids were able to stimulate UCP2 gene expression to a significant extent, along with a panel of genes encoding proteins known to be involved in cardiac fatty acid transport and metabolism, strongly suggests a relationship between UCP2 and fatty acid handling. 50, 16 An involvement of the uncoupling proteins has been hypothesized in the uncoupling effect of heart muscle mitochondria by high NEFA concentrations, 17, 18 that could decrease the ATP formation and the heart work efficiency in the diabetic rat. 51 More recently, however, the putative uncoupling effect of these proteins has been questioned. In fact UCP homologs were found to be upregulated in several different metabolic conditions characterized by increased NEFA availability, such as lipid infusion, food deprivation and streptozotocin-induced diabetes. 48, 52, 53 These observations are consistent with a role for UCP2 and UCP3 in the regulation of lipids as fuel substrates rather than as mediators of regulatory thermogenesis. The increase in UCP gene expression may lead to an increased export of fatty acid anions, allowing continued rapid fatty acid oxidation in the face of an oversupply, thus preventing the toxic effect of high NEFA levels. 54 Finally, another putative function of UCP2 and 3 could be the control of free radical production, 55 thus protecting the tissues from the oxidative damage. 56 In conclusion, our data show that an increased availability of NEFA induces a different pattern of (FAT)=CD36 gene expression between skeletal and heart muscle. Moreover the increased lipid supply impairs insulin sensitivity by affecting glucose uptake and GLUT4 gene expression in both tissues. At present we do not have a definitive answer to the question of whether the increase in both UCP2 and 3 we observed in the heart may merely be considered as an epiphenomenon linked to the final metabolism of NEFAs or may be viewed either as a pathogenetic mechanism or an attempt to prevent the toxic effect of high NEFA levels. All these data taken together suggest that lipotoxicity may affect not only skeletal muscle, but also heart metabolism in conditions characterized by high NEFA plasma levels, such as obesity and type 2 diabetes.
